SI
SPRB

Sofinnova Investments’s Spruce Biosciences SPRB Stock Holding History

Sofinnova Investments’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-304
Closed -$66.7K – 88
2023
Q4 		$66.7K Sell
304
-470
-61% -$54.3K ﹤0.01% 60
2023
Q3 		$131K Hold
774
– – 0.01% 65
2023
Q2 		$125K Buy
+774
New +$129K 0.01% 52

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sofinnova Investments's SPRB Position: Q1 2024 in Review

Sofinnova Investments sold out of Spruce Biosciences (SPRB) in Q1 2024, closing a stake of 304 shares — an estimated $66.7K sold.

Sofinnova Investments first reported a position in SPRB in Q2 2023 and held it in 3 quarters. The position peaked at $131K in Q3 2023. 49 funds tracked by Wall St. Rank hold SPRB as of Q1 2024.

  • Sofinnova Investments reported no remaining Spruce Biosciences position as of Q1 2024 after selling out during the quarter.
  • Sofinnova Investments sold 304 Spruce Biosciences shares in Q1 2024, an estimated $66.7K.
  • Sofinnova Investments first reported a position in Spruce Biosciences in Q2 2023 and held it in 3 quarters.
  • Sofinnova Investments's Spruce Biosciences position peaked at $131K in Q3 2023.
  • 49 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2024.

Based on Sofinnova Investments's 13F filing for Q1 2024, filed 15 May 2024.